FluoGuide has received an award from The Association of Listed Danish Growth Companies in the category of “Largest Stock Price Increase Since IPO”.
“We are very pleased by the recognition of our achievements since the IPO and our continuous commitment to improving outcomes for cancer patients,” says Morten Albrechtsen, CEO of FluoGuide. “The data we have generated has put FluoGuide in a uniquely promising position to move FG001 rapidly towards market and making a significant different to cancer patients.”
FluoGuide shares have increased more than ten times since the IPO
FluoGuide has made significant progress since its initial public offering (IPO) in 2019, generating positive phase II data on its lead product FG001, which is designed to improve surgical precision by illuminating cancer cells during surgery, across three indications – aggressive brain cancer, head & neck cancer, and lung cancer. This is enabling FluoGuide to take precision surgery to the next level, improving the outcome for cancer patients.
FluoGuide shares have increased more than ten times since the IPO. The Association of Listed Danish Growth Companies recognized this achievement at its Annual Meeting, and presented the award to FluoGuide CEO Morten Albrechtsen.
